A Case of Exacerbation of Haloperidol-Induced Rhabdomyolysis Following the Onset of COVID-19

Keisuke Takada; Yukiyoshi Sada; Masaru Samura; Masashi Matsuura; Naoki Hirose; Takenori Kurata; Fumio Nagumo; Junichi Ishii; Sakura Koshioka; Masaki Uchida; Junki Inoue; Koji Tanikawa; Hiroyuki Kunishima

doi:10.12659/AJCR.936589

20 June 2022 : Case report Japan

A Case of Exacerbation of Haloperidol-Induced Rhabdomyolysis Following the Onset of COVID-19

Unusual clinical course, Challenging differential diagnosis, Adverse events of drug therapy

Keisuke Takada^1ABDEF*, Yukiyoshi Sada^2ABDEF, Masaru Samura

^1ABDEF, Masashi Matsuura^1BDE, Naoki Hirose^1DE, Takenori Kurata^1DE, Fumio Nagumo^1DE, Junichi Ishii^1DE, Sakura Koshioka^1DE, Masaki Uchida^1DE, Junki Inoue^1DE, Koji Tanikawa^1DEF, Hiroyuki Kunishima^3ADEF

DOI: 10.12659/AJCR.936589

Am J Case Rep 2022; 23:e936589

Authors information Article notes Copyright and License information

Background Case Report Discussion Conclusions References:

Related articles Order reprints Share article Share by email

View HTML version

Figure 2. Clinical course of the patient. RDV – remdesivir; DEX – dexamethasone; mPSL – methylprednisolone; TCZ – tocilizumab; CI – continuous infusion; CK – creatine phosphokinase; SCr – serum creatinine.

Back to the Article

A Case of Exacerbation of Haloperidol-Induced Rhabdomyolysis Following the Onset of COVID-19

Your Privacy